Every pharmaceutical company dreams of having a pioneering blockbuster drug, i.e., one whose annual sales top $1 billion. But that's not a ticket to permanent, automatic success; case in point: Novo Nordisk (NYSE:NVO). The company rose to fame (after years of relative obscurity) with the semaglutide GLP-1 molecule in the twin blockbusters Ozempic and Wegovy. Over the past few years, however, the semaglutide siblings have come under competitive fire from numerous directions. As if that weren't enough, at Novo's investor day on Monday, CEO Mike Doustdar highlighted another risk making the company vulnerable -- semaglutide's looming patent cliff.
Wir zeigen den wichtigsten Punkt oeffentlich. Erstellen Sie ein kostenloses Konto, um den vollstaendigen Artikel zu lesen, ihn zu speichern, zu diskutieren und mit Markt- und OSINT-Kontext zu verbinden.